শুধুমাত্র তথ্যমূলক — চিকিৎসা পরামর্শ নয়। সর্বদা লাইসেন্সপ্রাপ্ত স্বাস্থ্যসেবা প্রদানকারীর পরামর্শ নিন।

MedBD
EN
Community data Updated 2 মাস আগে
🌐 View in English

ইঙ্গিত

Cancer

Bevixa is a vascular endothelial growth factor-specific angiogenesis inhibitor. It is indicated for the treatment of metastatic colorectal cancer, given with intravenous 5-fluorouracil-based chemotherapy as first- or second-line treatment. It is also indicated for metastatic colorectal cancer, given with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy as second-line treatment in patients whose disease has progressed on a first-line regimen containing Bevixa. It is indicated for non-squamous non-small cell lung cancer, given with carboplatin and paclitaxel as first-line treatment of unresectable, locally advanced, recurrent or metastatic disease. It is indicated for glioblastoma, used as a single agent in adult patients with progressive disease following prior therapy; the effectiveness of Bevixa here is based on improvement in objective response rate, and no data are available demonstrating improvement in disease-related symptoms or survival with Bevixa. It is indicated for metastatic renal cell carcinoma in combination with interferon alfa. It is indicated for cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, in persistent, recurrent, or metastatic disease. It is indicated for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer that is either (1) platinum-resistant, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, or (2) platinum-sensitive, in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Bevixa as a single agent. Limitation of use: Bevixa is not indicated for adjuvant treatment of colon cancer.

⚠️ কোনো ওষুধ গ্রহণের আগে সর্বদা নিবন্ধিত চিকিৎসকের পরামর্শ নিন।

ফার্মাকোলজি

Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in-vitro and in-vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab has an approximate molecular weight of 149 kD. Bevacizumab is produced in a mammalian cell (Chinese Hamster Ovary) expression system in a nutrient medium containing the antibiotic gentamicin. Gentamicin is not detectable in the final product. Bevacizumab is a clear to slightly opalescent, colorless to pale brown, sterile, pH 6.2 solution for intravenous infusion.

Pregnancy & Breastfeeding

Pregnancy: Based on animal studies and its mechanism of action, bevacizumab may cause fetal harm.

Lactation: No data are available on whether bevacizumab passes into human milk, or on its effects on milk production or on a breastfed infant. Human IgG is known to be present in breast milk, but published data suggest that antibodies in breast milk do not enter the neonatal and infant circulation in significant amounts. Because of the risk of serious adverse reactions in breastfed infants, nursing mothers are advised not to breastfeed while being treated with Bevacizumab.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

ডোজ নির্দেশিকা

⚠️ শুধুমাত্র সরকারি উৎস থেকে নির্দেশিকা পরিসীমা। ব্যক্তিগতকৃত ডোজের জন্য আপনার ডাক্তারের পরামর্শ নিন।

Adults: Dosage: Patients should continue treatment until the disease progresses or the side effects become unacceptable. Metastatic Colorectal Cancer (mCRC): The recommended doses are 5 mg/kg or 10 mg/kg every 2 weeks when used in combination with intravenous 5-FU-based chemotherapy. Give 5 mg/kg when used in combination with bolus-IFL. Give 10 mg/kg when used in combination with FOLFOX4. Give 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks when used in combination with a fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy regimen in patients whose disease has progressed on a first-line Bevacizumab-containing regimen. Non-Squamous Non-Small Cell Lung Cancer (NSNSCLC): The recommended dose is 15 mg/kg every 3 weeks in combination with carboplatin and paclitaxel. Glioblastoma: The recommended dose is 10 mg/kg every 2 weeks. Metastatic Renal Cell Carcinoma (mRCC): The recommended dose is 10 mg/kg every 2 weeks in combination with interferon alfa. Cervical Cancer: The recommended dose of Bevacizumab is 15 mg/kg every 3 weeks, given as an intravenous infusion in combination with one of the following chemotherapy regimens: paclitaxel and cisplatin, or paclitaxel and topotecan. Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer: The recommended dose is 10 mg/kg every 2 weeks in combination with one of the following intravenous chemotherapy regimens: paclitaxel, pegylated liposomal doxorubicin, or topotecan (weekly); or 15 mg/kg every 3 weeks in combination with topotecan (every 3 weeks). Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: The recommended dose is 15 mg/kg every 3 weeks when given in combination with carboplatin and paclitaxel for 6 cycles and up to 8 cycles, followed by continued use of Bevacizumab 15 mg/kg every 3 weeks as a single agent until the disease progresses. Alternatively, 15 mg/kg every 3 weeks when given in combination with carboplatin and gemcitabine for 6 cycles and up to 10 cycles, followed by continued use of Bevacizumab 15 mg/kg every 3 weeks as a single agent until the disease progresses.

পার্শ্বপ্রতিক্রিয়া ও পারস্পরিক ক্রিয়া

পার্শ্বপ্রতিক্রিয়া

No side-effect data recorded yet.

প্রধান পারস্পরিক ক্রিয়া

Checker →